Resistance Mutation Profiles in Non-Small Cell Lung Cancer: Key Findings and Implications

Strategic Insights -

New research from Johnson & Johnson has shed light on the complex resistance mechanisms in non-small cell lung cancer (NSCLC) associated with current treatments. The study, published in Current Oncology, notes that treatment resistance due to gene alterations remains a significant challenge for patients with EGFR-mutated advanced or metastatic NSCLC. A systematic literature review identified 45 included studies, revealing a strong association between EGFR-dependent and independent mechanisms of resistance and poor clinical outcomes. The study highlights the need for addressing heterogeneous resistance profiles and improving outcomes for patients with EGFR-mutated a/mNSCLC.

Key Takeaways:

  • The study found that EGFR-dependent resistance mechanisms, such as the T790M loss and C797X mutation, were more frequent in first-line and second-line osimertinib treatments, respectively.
  • EGFR-independent mechanisms, including MET amplification, TP53 mutation, and CCNE1 amplification, were also identified as contributors to resistance.
  • The most common treatment for NSCLC was osimertinib, followed by other tyrosine kinase inhibitors and non-TKIs.
  • The study concluded that addressing heterogeneous resistance profiles through novel therapies is crucial for improving outcomes in patients with EGFR-mutated a/mNSCLC.
  • The research involved a comprehensive search of MEDLINE and Embase, identifying 2986 records from 2018 to August 2022.
  • Osimertinib was the most commonly reported treatment, with 15 studies reporting its use alone and 18 studies reporting its use as one of the treatment options.
  • The study highlighted the importance of identifying specific resistance mechanisms to inform personalized treatment approaches.

Statistics:

  • 2986 records were identified in the systematic literature review conducted from 2018 to August 2022.
  • 145 studies reported the use of osimertinib, with 21 studies reporting its use in combination with other treatments.
  • 20% to 49% of patients experienced T790M loss in second-line osimertinib treatment.
  • 2.9% to 12.5% of patients in first-line osimertinib treatment experienced C797X mutation.
  • 0.6% to 66% of patients in first-line treatment experienced MET amplification.
  • 7.2% to 19% of patients in second-line treatment experienced MET amplification.
  • 29.2% to 33.3% of patients in first-line treatment experienced TP53 mutation.
  • 10.3% of patients in second-line treatment experienced CCNE1 amplification.

Sources:

  • NewsRx. Johnson & Johnson Researchers Publish New Data on Non-Small Cell Lung Cancer (Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A ...). Cancer Weekly. May 13, 2025; p 125.
  • Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review. Current Oncology, 2025, 32(4): 191.